Stock Markets
EU approves TEPKINLY for certain lymphoma treatments
COPENHAGEN – The European Commission has granted conditional marketing authorization to Genmab (NASDAQ:) A/S’s TEPKINLY (epcoritamab), making it the first subcutaneous bispecific antibody approved in the European Union for monotherapy treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after at least two lines of systemic therapy. This approval also extends to the European Economic Area countries and Northern Ireland.
Follicular lymphoma, a typically slow-growing form of non-Hodgkin’s lymphoma, accounts for 20-30% of all non-Hodgkin’s lymphoma cases and is considered incurable with no standard third-line treatment. The authorization of TEPKINLY offers a new treatment option for patients who have exhausted other therapies and often face relapse.
The approval is based on data from the Phase 1/2 EPCORE NHL-1 clinical trial, which showed an overall response rate of 83% and a complete response rate of 63% in patients treated with TEPKINLY. At a median follow-up of 16.2 months, the median duration of response was 21.4 months, with the duration of complete response not yet reached. The trial also demonstrated a favorable safety profile, with the most common adverse reactions being cytokine release syndrome, injection site reactions, and fatigue.
Genmab, in partnership with AbbVie (NYSE:), is committed to further development of epcoritamab as a potential core therapy for B-cell malignancies. The companies plan to pursue additional international regulatory approvals for R/R FL and R/R diffuse large B-cell lymphoma (DLBCL) indications.
The approval has been welcomed by the lymphoma community, as it represents a significant advancement in the treatment options available for patients with this challenging form of cancer.
This news article is based on a press release statement from Genmab A/S, an international biotechnology company focused on developing innovative antibody therapeutics for cancer treatment. The information provided here is intended for general informational purposes and should not be considered as medical advice. The safety and efficacy of TEPKINLY for investigational uses have not been established. For detailed safety information, please refer to the full Summary of Product Characteristics or the prescribing information in your region.
In other recent news, Genmab A/S has reported a capital increase resulting from employee warrant exercises. This development is part of the company’s internal incentive programs aimed at retaining employees. The company has not disclosed the number of warrants exercised or the amount of capital raised. Genmab, known for its work in the development of antibody therapeutics, has also disclosed transactions with shares and linked securities by managerial employees and their closely associated persons.
In financial news, Genmab has reported strong financial results for the first half of 2024, with a significant revenue growth of 36% to over DKK 9.5 billion and a 29% increase in operating profit to DKK 2.4 billion. The company’s drugs, DARZALEX, KESIMPTA, and EPKINLY, have contributed significantly to these figures. Genmab has also completed the acquisition of ProfoundBio, which is expected to enhance its long-term growth potential.
Despite potential volatility in their tax rate due to the integration of ProfoundBio operations, Genmab anticipates this to normalize within 12 to 18 months. The company is not actively seeking a partner for acasunlimab but may consider regional partnerships in the future. These are among the recent developments at Genmab.
InvestingPro Insights
In light of Genmab A/S’s recent European Commission approval for TEPKINLY, the company’s financial health and stock performance become a focal point for investors. Genmab’s market capitalization stands at a robust 17.47 billion USD, reflecting investor confidence in the company’s value and growth potential. The company’s P/E ratio, a key indicator of investor expectations for earnings growth, is 21.76, aligning with industry standards and suggesting a balanced valuation relative to its earnings.
Significantly, Genmab holds more cash than debt on its balance sheet, a strong indicator of financial stability and an InvestingPro Tip that highlights the company’s solid liquidity position. This financial footing could be instrumental in supporting ongoing research and development efforts, such as the further development of epcoritamab for B-cell malignancies. Additionally, Genmab’s revenue growth over the last twelve months has been impressive at 17.19%, signaling a healthy increase in the company’s financial inflows, which is essential for fuelling its strategic initiatives.
Investors may also take note of another InvestingPro Tip: Genmab’s management has been actively engaging in share buybacks, a move that often reflects leadership’s belief in the company’s future prospects and can be seen as a positive sign for shareholders. For those looking to delve deeper into the company’s financials and stock performance, there are over 10 additional InvestingPro Tips available at https://www.investing.com/pro/GMAB, offering comprehensive insights into Genmab’s market position and future outlook.
With Genmab’s commitment to advancing cancer treatment and its strong financial metrics, the company appears well-positioned to navigate the competitive landscape of the biotechnology industry and deliver value to both patients and investors alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
14 lessons from 2024 to remember in 2025: BofA
Investing.com — In a recent note, Bank of America outlined 14 key lessons from 2024 that investors should keep in mind as they head into 2025, warning that market momentum and stretched valuations could face headwinds in the year ahead.
While this year resembled the steady gains of 1996-97, rather than the bubble peaks of 1998-99, risks are mounting—from geopolitical tensions and rising debt to market fragility highlighted by the VIX.
BofA points to opportunities in Europe, China, and Japan but cautions that volatility, trade disputes, and macroeconomic uncertainty will shape the next leg of the market cycle.
Below are the 14 lessons that BofA highlighted.
1. 2024 was a strong year for markets, but it might only be the beginning.
2. The market’s performance in 2024 looked more like the steady gains of 1996-97 than the bubble peaks of 1998-99.
3. In a bubble environment, market leadership can persist for longer than investors can afford to stay underweight.
4. However, the combination of strong momentum and high valuations is already too stretched to avoid a potential bust.
5. The has shown that markets remain fragile, and a major shock may be overdue.
6. August 2024 suggests buying market dips and locking in volatility spikes; using smarter strategies like skewed delta positioning may be key for 2025.
7. Rising debt levels and persistent inflation mean bond vigilantes remain the most visible macroeconomic tail risk.
8. Market fragility, faster reactions, and elevated valuations suggest a repeat of the calm volatility seen in 2017 is unlikely.
9. A Trump election victory has reignited concerns around tariffs, with European companies favored by dollar strength potentially becoming the next trade targets.
10. European equities remain cheap and unloved—investors should be cautious about being caught short, as fewer crowded trades mean less volatility pain.
11. China’s outperformance over Japan in 2024 could continue if U.S. interest rates decline.
12. VIX options data indicates that positioning risks in the market have not gone away.
13. Eurozone bank dividends have outperformed the for much of the past year; investors may need to hedge against a different outcome in 2025.
14. The risk of sharp movements in the Japanese yen, driven by volatility, could cause instability for the in 2025.
Stock Markets
Class Action Lawsuit Reminder WOLF: Kessler Topaz Meltzer & Check, LLP Reminds Wolfspeed, Inc. (WOLF) Investors – A Securities Fraud Class Action Lawsuit Has Been Filed
RADNOR, PA. – (NewMediaWire) – December 21, 2024 – The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Wolfspeed (NYSE:), Inc. (Wolfspeed) (NYSE: WOLF) on behalf of those who purchased or otherwise acquired Wolfspeed securities between August 16, 2023, and November 6, 2024, inclusive (the Class Period). The lead plaintiff deadline is January 17, 2025.
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered Wolfspeed losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/wolfspeed-inc?utm_source=PR&utm_medium=link&utm_campaign=wolf&mktm=r
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com .
DEFENDANTS ALLEGED MISCONDUCT:
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Wolfspeeds optimistic claims of potential growth of its Mohawk Valley fabrication facility and general demand for Wolfspeeds 200mm wafers in the electronic vehicle market fell short of reality; and (2) Wolfspeed had overstated demand for its key product and placed undue reliance on purported design wins while the Mohawk Valley facilitys growth had begun to taper before recognizing the $100 million revenue per quarter allegedly achievable with only 20% utilization of the fabrication, let alone the promised $2 billion revenue purportedly achievable by the facility.
Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/zMLfnSRjg2Y
THE LEAD PLAINTIFF PROCESS:
Wolfspeed investors may, no later than January 17, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Wolfspeed investors who have suffered significant losses to contact the firm directly to acquire more information.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaints in this action were not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .
CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
info@ktmc.com
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
View the original release on www.newmediawire.com
Copyright 2024 JCN Newswire . All rights reserved.
Stock Markets
Starbucks workers’ union strikes across US as talks hit impasse
By Savyata Mishra, Gursimran Mehar and Renee Hickman
(Reuters) -Some members of the Starbucks (NASDAQ:) workers’ union that represents more than 10,000 baristas walked off their jobs in multiple U.S. cities on Friday, citing unresolved issues over wages, staffing and schedules.
The five-day strike, which began on Friday and closed Starbucks cafes in Los Angeles, Chicago and Seattle, will expand to Columbus (WA:), Denver, and Pittsburgh through Saturday, the union said in a statement.
This is the latest in a series of labor actions that have picked up pace across service industries following a period when workers at manufacturers in the automotive, aerospace and rail industries won substantial concessions from employers.
At Starbucks, the Workers United union, which represents employees at 525 stores across the U.S., said late on Thursday that walkouts would escalate daily, and could reach “hundreds of stores” nationwide by Christmas Eve.
“It’s estimated that 10 stores out of 10,000 company-operated stores did not open today,” Starbucks said, adding that there was no significant impact to store operations on Friday.
Around 20 people joined a picket line at a Starbucks location on Chicago’s north side, buffeted by snow and wind, but cheering in response to the honking horns of passing cars.
A few confused customers tried to walk into the closed store before strikers began chanting, but union member Shep Searl said the reaction had been mostly positive.
Searl said 100% of the unionized workers at the Starbucks location in Chicago’s Edgewater neighborhood were participating in the strike, and according to the workers, they have been subject to numerous unfair labor practices including write-ups, “captive-audience” meetings and firings.
The union member said they made about $21 an hour and added, “that would have been a great wage in 2013”.
It is an inadequate wage, the baristas said, given inflation and the high cost of living in a large city, especially since they rarely get 40-hour work weeks.
WORKERS SNUB OFFER
Negotiations between the company and Workers United began in April, based on an established framework agreed upon in February, which could also help resolve numerous pending legal disputes.
The company said on Thursday it has held more than nine bargaining sessions with the union since April, and reached more than 30 agreements on “hundreds of topics”, including economic issues.
The Seattle-headquartered firm said it is ready to continue negotiations, claiming the union delegates prematurely ended the bargaining session this week.
The union, however, said in a Facebook (NASDAQ:) post on Friday that Starbucks had yet to present a serious economic proposal with less than two weeks remaining until the year-end contract deadline.
The workers’ group also snubbed an offer of no immediate wage hike and a guarantee of a 1.5% increase in future years.
“Workers United proposals call for an immediate increase in the minimum wage of hourly partners by 64%, and by 77% over the life of a three-year contract. This is not sustainable,” Starbucks said on Friday.
In response to Starbucks’ statement on the proposals, Michelle Eisen, a Starbucks barista and bargaining delegate, said, “Starbucks’ characterization of our proposals is misleading and they know it. We are ready to finalize a framework that includes new investments in baristas in the first year of contracts”.
Separately, the baristas’ union said on Friday that it filed a new labor practice charge against the coffee house, alleging Starbucks “refused to bargain and engaged in bad faith bargaining” over economic issues.
Hundreds of complaints have been filed with the National Labor Relations Board (NLRB), accusing Starbucks of unlawful labor practices such as firing union supporters and closing stores during labor campaigns. Starbucks has denied wrongdoing and said it respects the right of workers to choose whether to unionize.
WORKING ON A TURNAROUND
Last month, the NLRB said that Starbucks broke the law by telling workers at its flagship Seattle cafe that they would lose benefits if they joined a union.
“It’s (the strike) taking place during one of the busiest times of the year for Starbucks, which could magnify its impact while bringing unwanted public scrutiny into the company’s labor practices,” Emarketer analyst Rachel Wolff said.
The coffee chain is working on a turnaround under its newly appointed top boss, Brian Niccol, who aims to restore “coffee house culture” by overhauling cafes and simplifying its menu among other measures.
“Given how much Starbucks is already struggling to win over customers, it can ill afford any negative publicity – or impact to sales – that the strike could bring,” Wolff said.
The Starbucks workers’ strike comes in the same week as Amazon.com (NASDAQ:) workers at seven U.S. facilities walking off the job on Thursday, during the holiday shopping rush.
There were 33 work stoppages in 2023, the most since 2000, though far lower than in past decades, data from the U.S. Bureau of Labor Statistics showed.
- Forex2 years ago
Forex Today: the dollar is gaining strength amid gloomy sentiment at the start of the Fed’s week
- Forex2 years ago
How is the Australian dollar doing today?
- Forex2 years ago
Unbiased review of Pocket Option broker
- Forex2 years ago
Dollar to pound sterling exchange rate today: Pound plummeted to its lowest since 1985
- Cryptocurrency2 years ago
What happened in the crypto market – current events today
- World2 years ago
Why are modern video games an art form?
- Commodities2 years ago
Copper continues to fall in price on expectations of lower demand in China
- Forex2 years ago
The dollar is down again against major world currencies